GLP-1 Receptors in the Brain Control Spinal Fluid Production and Brain Pressure | Research

The takeaway

GLP-1 receptors on the brain's choroid plexus directly regulate cerebrospinal fluid production — activating them increases brain pressure, while blocking them reduces it.

Bidirectional control
Activating GLP-1 receptors in the choroid plexus increased CSF production and brain pressure, while blocking them reduced it — but only when drugs were delivered directly to the brain

What the researchers found

GLP-1 receptors on the choroid plexus (the brain structure that produces cerebrospinal fluid) directly modulate CSF production and intracranial pressure in rats. When researchers activated GLP-1 receptors centrally (directly in the brain), CSF secretion increased and intracranial pressure rose. When they blocked GLP-1 receptors, CSF secretion decreased. Crucially, these effects only occurred with central (brain) administration — not peripheral (body) injection — indicating the relevant receptors are on the CSF-facing side of the choroid plexus.

GLP-1R expression was confirmed in the choroid plexus at both mRNA and protein levels, and the receptor modulated transporter activity in the choroid plexus tissue.

Why it matters

This is a mechanistically important study for two reasons: (1) It provides a potential explanation for how GLP-1 drugs might help conditions like idiopathic intracranial hypertension — by modulating CSF production through choroid plexus GLP-1 receptors. (2) It reveals that GLP-1 signaling in the brain directly affects a fundamental physiological process (CSF dynamics) that, if dysregulated, can be fatal. This opens a new pharmacological target for conditions with elevated intracranial pressure.

The numbers in context

GLP-1R agonist: exendin-4 · GLP-1R antagonist: exendin-9-39 · Central (i.c.v.) administration effective · Peripheral (i.p.) not effective · GLP-1R confirmed in choroid plexus (mRNA + protein) · CSF secretion rate modulated bidirectionally

How the study worked

Male rats received either a GLP-1R agonist (exendin-4) or antagonist (exendin-9-39) via intraperitoneal or intracerebroventricular injection. CSF secretion rate and intracranial pressure were measured in vivo. GLP-1R expression in the choroid plexus was confirmed using RNAScope in situ hybridization and western blotting. Transporter activity was assessed using radio-isotope flux assays in excised choroid plexus tissue.

Who was studied

Male Sprague-Dawley rats (in vivo CSF dynamics and ex vivo choroid plexus studies)

What this study cannot tell us

Rat study — the choroid plexus GLP-1R expression and CSF dynamics may differ in humans. The central (i.c.v.) administration route used in the key experiments delivers drugs directly to the brain, which is very different from how GLP-1 drugs are taken clinically (subcutaneous injection). Whether peripherally administered GLP-1 drugs reach brain GLP-1 receptors at sufficient concentrations to affect CSF production in humans is unknown. GLP-1R expression in the choroid plexus was described as 'low level.'

How to read the evidence

This is a well-designed mechanistic animal study using multiple complementary techniques (in vivo CSF dynamics, receptor localization, transporter assays). It provides strong preclinical evidence for the mechanism but is limited to rats with central drug delivery.

When this study was published

Published in 2025. This is very current research that provides a mechanistic explanation for the emerging clinical use of GLP-1 drugs in intracranial hypertension.

The bigger picture

This study provides the mechanistic basis for clinical observations that GLP-1 drugs may help patients with idiopathic intracranial hypertension (IIH). By showing exactly where and how GLP-1 receptors modulate CSF production, it opens the door to rational drug design for IIH and other conditions with elevated intracranial pressure — for which current treatment is limited to invasive surgery. The finding that peripheral GLP-1R agonists didn't affect CSF dynamics raises important questions about whether clinical GLP-1 drugs actually reach the relevant brain receptors.

Questions still open

Do clinically used GLP-1 drugs (semaglutide, tirzepatide) cross the blood-brain barrier in sufficient amounts to modulate choroid plexus CSF production in humans?
Could a GLP-1R antagonist delivered directly to the brain become a treatment for idiopathic intracranial hypertension?
Does the observed increase in CSF production from GLP-1R activation have any implications for brain clearance of metabolic waste (glymphatic system)?

Common questions

Could GLP-1 drugs help people with high brain pressure?

This study shows the mechanism exists — GLP-1 receptors on the choroid plexus can control how much cerebrospinal fluid the brain produces. But the effect only worked when drugs were delivered directly to the brain, not through peripheral injection. Whether clinical GLP-1 drugs like semaglutide reach the brain in sufficient amounts to have this effect in humans is still an open question.

What is the choroid plexus?

The choroid plexus is a network of blood vessels and tissue inside the brain's ventricles that produces cerebrospinal fluid — the liquid that surrounds and protects your brain and spinal cord. When it produces too much fluid, intracranial pressure rises dangerously.

Read the original research

Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.

Fluids and barriers of the CNS, 22(1), 41

View on PubMed ↗Publisher’s paper ↗

Citation

Jensen, Mette N; Israelsen, Ida M E; Wardman, Jonathan H; Jensen, Dennis B; Andersen, Daniel B; Toft-Bertelsen, Trine L; Rath, Martin F; Holst, Jens Juul; Rosenkilde, Mette M; MacAulay, Nanna. (2025). Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.. Fluids and barriers of the CNS, 22(1), 41. https://doi.org/10.1186/s12987-025-00652-x